search
Back to results

Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms (BOMP)

Primary Purpose

Parkinson Disease

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms
Sponsored by
Fondation Ophtalmologique Adolphe de Rothschild
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Parkinson Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient over 18 years old
  • Follow-up for Parkinson's disease for more than 5 years
  • Treatment stable for at least 3 months
  • Having retained sufficient autonomy to allow participation in the study
  • Hoehn and Yahr score in ON DOPA <4

Exclusion Criteria:

  • Genetic forms of the disease
  • EVA> 7 over the previous week
  • Moderate to severe cognitive impairment
  • Pathology or condition (other than Parkinson's disease) that can generate motor disorders
  • Allergy to metals and / or silicone
  • Dermatological pathology on the wrists
  • Metal object at one of the wrists (implanted metal material, piercing)
  • Presence of a tattoo on one of the wrists
  • Wrist circumference <14.5 cm or> 21 cm i.e. wrist incompatible with the MD template
  • Inability of the patient to put on and / or wear the template of the medical device
  • Pregnant or breastfeeding woman

Sites / Locations

  • Hopital Fondation Adolphe de Rothschild
  • Centre Hospitalier de Voiron

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

VERUM

SHAM

Arm Description

An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months

An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.

Outcomes

Primary Outcome Measures

Assessment of the effectiveness of two months of use of the Remedee Endorphin Band medical device in improving motor disorders in patients with Parkinson's disease
The Movement Disorder Society Unified Parkinson Disease Rating Scale III (MDS-UPDRS III score evaluation see Appendix 1) will be performed under ON Dopa conditions and blinded from the randomization arm. The MDS-UPDRS III evaluates various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. Each parkinsonian sign or symptom is rated on a 5-point Likert-type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total MDS-UPDRS III score is 199, indicating the worst possible disability from Parkinson disease.

Secondary Outcome Measures

Full Information

First Posted
November 19, 2020
Last Updated
September 15, 2023
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Collaborators
Remedee SA
search

1. Study Identification

Unique Protocol Identification Number
NCT04648150
Brief Title
Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms
Acronym
BOMP
Official Title
Evaluation of a Millimeter Wave Emission Bracelet -Type Medical Device for Improving Parkinson's Disease Symptoms: Multicenter, Double-blind Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
May 18, 2021 (Actual)
Primary Completion Date
May 5, 2023 (Actual)
Study Completion Date
May 5, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Collaborators
Remedee SA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Idiopathic Parkinson's disease is a common neurodegenerative disease, with a prevalence of around 2% in people over 65 years of age in France. This pathology affects the dopaminergic pathway but also other systems: cholinergic, noradrenergic and serotoninergic. The symptoms of Parkinson's disease are motor but also non-motor with sleep, smell, cognitive, psychiatric, digestive, urinary, dysautonomic, painful disorders. The discomfort can be such that invasive and expensive solutions have been developed. Invasive or expensive techniques (deep brain stimulation, lesional microsurgery by gamma knife or ultrasound, duodopa or apokinon pumps) brought significant benefits to patients. Opportunities for clinical improvement using less expensive and lighter devices should be sought. The Remedee endorphin band device is a device that emits millimeter-band electromagnetic waves on the wrist. The device stimulates subcutaneous nerve endings and activates a physiological response leading to the release of endorphins in the brain. Endorphins are involved in several physiological processes, including pain control. Mu-opioid receptor (MOR) agonists do not only relieve pain, but have effects related to mesolimbic dopaminergic pathways. Indeed, the opioid and dopaminergic systems are closely linked at the cellular level. Endorphins, through inhibition of the release of the neurotransmitter GABA upon binding to the μ receptor, are also linked to an increase in dopamine.
Detailed Description
Intervention 1 Name : VERUM Description : Experimental arm (VERUM): delivery of an active medical device for a period of 2 months. Then delivery of a second active medical device for a period of 4 months. Intervention 2 Name : SHAM Description: Control arm (SHAM): delivery of an inactive medical device for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Experimental arm (VERUM): delivery of an active medical device for a period of 2 months. Then delivery of a second active medical device for a period of 4 months. Control arm (SHAM): delivery of an inactive medical device for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.
Masking
ParticipantCare ProviderInvestigator
Masking Description
ratio 1 :1 in each centre on an online randomization module
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VERUM
Arm Type
Experimental
Arm Description
An active wave emission bracelet for a period of 2 months. Then delivery of a second active medical device for a period of 4 months
Arm Title
SHAM
Arm Type
Sham Comparator
Arm Description
An inactive wave emission bracelet for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion.
Intervention Type
Device
Intervention Name(s)
Evaluation of a millimeter wave emission bracelet for improving Parkinson's disease symptoms
Intervention Description
Evaluation of a millimeter wave emission bracelet -type medical device for improving Parkinson's disease symptoms: multicenter, double-blind randomized controlled trial
Primary Outcome Measure Information:
Title
Assessment of the effectiveness of two months of use of the Remedee Endorphin Band medical device in improving motor disorders in patients with Parkinson's disease
Description
The Movement Disorder Society Unified Parkinson Disease Rating Scale III (MDS-UPDRS III score evaluation see Appendix 1) will be performed under ON Dopa conditions and blinded from the randomization arm. The MDS-UPDRS III evaluates various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. Each parkinsonian sign or symptom is rated on a 5-point Likert-type scale (ranging from 0 to 4), with higher scores indicating more severe impairment. The maximum total MDS-UPDRS III score is 199, indicating the worst possible disability from Parkinson disease.
Time Frame
two months after inclusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient over 18 years old Follow-up for Parkinson's disease for more than 5 years Treatment stable for at least 3 months Having retained sufficient autonomy to allow participation in the study Hoehn and Yahr score in ON DOPA <4 Exclusion Criteria: Genetic forms of the disease EVA> 7 over the previous week Moderate to severe cognitive impairment Pathology or condition (other than Parkinson's disease) that can generate motor disorders Allergy to metals and / or silicone Dermatological pathology on the wrists Metal object at one of the wrists (implanted metal material, piercing) Presence of a tattoo on one of the wrists Wrist circumference <14.5 cm or> 21 cm i.e. wrist incompatible with the MD template Inability of the patient to put on and / or wear the template of the medical device Pregnant or breastfeeding woman
Facility Information:
Facility Name
Hopital Fondation Adolphe de Rothschild
City
Paris
ZIP/Postal Code
75019
Country
France
Facility Name
Centre Hospitalier de Voiron
City
Voiron
ZIP/Postal Code
38506
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms

We'll reach out to this number within 24 hrs